Rhupus Syndrome and Efficacy of Etanercept Treatment

Yang Beibei6 enrolled

Overview

between March 2013 and March 2014, Rhupus patients were enrolled to receive a 25-mg etanercept injection subcutaneously twice a week. The follow-up time of the study was 24 weeks.

between March 2013 and March 2014, patients who were unresponsive to therapy with corticosteroid and disease-modifying antirheumatic drugs (DMARDs), with a Disease Activity Score in 28 Joints (DAS28) \>5.1 were enrolled to receive a 25-mg etanercept injection subcutaneously twice a week. The follow-up time of the study was 24 weeks.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Rhupus Syndrome, Etanercept

Interventions

etanerceptDRUG

25-mg etanercept injection subcutaneously twice a week

Eligibility

Sex: ALLMin age: 18 YearsMax age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: \- Rhupus patients who were unresponsive to therapy with corticosteroid and disease-modifying antirheumatic drugs (DMARDs), with a Disease Activity Score in 28 Joints (DAS28) \>5.1 Exclusion Criteria: \- those who had participated in other studies

Outcomes

Primary Outcomes

Disease Activity Score in 28 Joints (DAS28)

Time frame: 24 week

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.